ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2026
Antimicrobial blue light against healthcare-related Candida species: in vitro efficacy and following repeated exposure for 30 days.
Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Antifungal resistance and invasive fungal infections are increasing mainly due to the lack of effective diagnostic methods and therapeutic options. The World Health Organization has formally designated several fungal pathogens as a major public health concern, including Candida spp. Indeed, the presence of fungal pathogens in hospitals represents a reservoir that persists in the areas and equipment surrounding patients. Therefore, the application of disinfection measures is imperative to reduce microbial contamination and disrupt transmission routes.Antimicrobial blue light (aBL) has emerged as a novel disinfection method. The present study evaluated the efficacy of aBL, with a combination of wavelengths of 405 nm and 430 - 470 nm, in inactivating Candida species over 8 h. Furthermore, the most susceptible strain was repeatedly exposed to aBL for 30 days, and its phenotypic characteristics were assessed throughout the experiment.Exposure to aBL has demonstrated to exhibit a dose-dependent antifungal effect across all the Candida species examined. The most tolerant species was C. albicans, followed by C. auris and C. parapsilosis. C. glabrata was the most susceptible species. Despite being repeatedly exposed for 30 days to a dose corresponding to 11% survival, C. glabrata demonstrated no alterations in its response to aBL, nor did it exhibit any change in antifungal susceptibility or in its capacity to form biofilm.In summary, the evidence suggests that aBL disinfection may be a safe approach for Candida decontamination, as it neither induces photo-tolerance in the most susceptible C. glabrata strain nor compromises its phenotypic characteristics.
Indexed as
Identifiers
42570186What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.